Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice

Jackevicius, 2002, Adherence with statin therapy in elderly patients with and without acute coronary syndromes, JAMA, 288, 462, 10.1001/jama.288.4.462 Pedersen, 2004, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S).1994, Atheroscler Suppl, 5, 81, 10.1016/j.atherosclerosissup.2004.08.027 Corsini, 1999, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol Ther, 84, 413, 10.1016/S0163-7258(99)00045-5 Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Waters, 2004, Treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?, Am J Cardiol, 93, 154, 10.1016/j.amjcard.2003.09.031 Scheen, 2006, The IDEAL study comparing simvastatin 20-40mg versus atorvastatin 80mg for secondary prevention after myocardial infarction: between two ideas of the ideal, Rev Med Liege, 61, 53 Lohse, 2003, What is the role of beta-adrenergic signaling in heart failure?, Circ Res, 93, 896, 10.1161/01.RES.0000102042.83024.CA Xiao, 2018, IL-18 cleavage triggers cardiac inflammation and fibrosis upon beta-adrenergic insult, Eur Heart J, 39, 60, 10.1093/eurheartj/ehx261 Al-Rasheed, 2015, Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway, Drug Des Devel Ther, 9, 3217 Hippisley-Cox, 2010, Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database, BMJ, 340, c2197, 10.1136/bmj.c2197 Zhang, 2013, Discontinuation of statins in routine care settings: a cohort study, Ann Intern Med, 158, 526, 10.7326/0003-4819-158-7-201304020-00004 Pasternak, 2002, ACC/AHA/NHLBI clinical advisory on the use and safety of statins, J Am Coll Cardiol, 40, 567, 10.1016/S0735-1097(02)02030-2 Tubic-Grozdanis, 2008, Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms, Pharm Res, 25, 1591, 10.1007/s11095-007-9519-6 Pouponneau, 2011, Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation, Biomaterials, 2, 3481, 10.1016/j.biomaterials.2010.12.059 Al-Jamal, 2011, Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine, Acc Chem Res, 44, 1094, 10.1021/ar200105p Li, 2013, Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy, Int J Nanomedicine, 8, 1285, 10.2147/IJN.S41695 Mikhaylov, 2011, Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment, Nat Nanotechnol, 6, 594, 10.1038/nnano.2011.112 Ullrich, 1986, Contraluminal transport of small aliphatic carboxylates in the proximal tubule of the rat kidney in situ, Pflugers Arch, 407, 488, 10.1007/BF00657505 Qi, 2015, G5 PAMAM dendrimer versus liposome: a comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin, Nanomedicine, 11, 1141, 10.1016/j.nano.2015.02.011 Tuerdi, 2016, Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice, Nanomedicine, 12, 1899, 10.1016/j.nano.2016.05.002 Costa, 2013, Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin, Eur J Pharmacol, 701, 82, 10.1016/j.ejphar.2013.01.001 Rabkin, 2003, Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors, Toxicol Appl Pharmacol, 193, 346, 10.1016/j.taap.2003.08.009 Rabkin, 2007, Reduction of protein synthesis and statin-induced cardiomyocyte cell death, Cardiovasc Toxicol, 7, 1, 10.1007/s12012-007-0003-7 Staffa, 2002, Cerivastatin and reports of fatal rhabdomyolysis, N Engl J Med, 346, 539, 10.1056/NEJM200202143460721 Thompson, 2003, Statin-associated myopathy, JAMA, 289, 1681, 10.1001/jama.289.13.1681 Ballantyne, 2003, Risk for myopathy with statin therapy in high-risk patients, Arch Intern Med, 163, 553, 10.1001/archinte.163.5.553 Demyanets, 2006, Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro, Biochem Pharmacol, 71, 1324, 10.1016/j.bcp.2006.01.016 Heather, 2009, Isoproterenol induces in vivo functional and metabolic abnormalities: similar to those found in the infarcted rat heart, J Physiol Pharmacol, 60, 31 Jiang, 2016, Effect of three statins on glucose uptake of cardiomyocytes and its mechanism, Med Sci Monit, 22, 2825, 10.12659/MSM.897047 Goyal, 2005, Liposomal drug delivery systems–clinical applications, Acta Pharm, 55, 1 Mugabe, 2006, Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 50, 2016, 10.1128/AAC.01547-05 Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Satoh, 1995, Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts, Br J Pharmacol, 116, 1894, 10.1111/j.1476-5381.1995.tb16679.x